## **BEAR Work-Sheet (Title):** Urine collection technique for Chlamydia infection

<b>Date</b> : Sept. 28, 2011
s comparable in their accuracy
Summary/Review Sites: □□ _primary research paper_)
le
Summary

□□ I do **not** want my BEAR (name removed) on the Dept EBM Website

## BEAR Work-Sheet (Title): \_Medication for BPPV\_\_\_\_ Name of Resident: **Date**: Sept. 21, 2011 **Question**: Does medication work for BPPV? **Search**: (Check all that apply) Pubmed/Ovid/Medline: □□ Filtered Resources: □□ Summary/Review Sites: □□ College/Society/Guidelines: ☑□ Other: □ (Describe: \_\_\_\_\_) Number of Resources Reviewed: \_3\_\_ **Resources** (Top 3) **#1 Resource:** Abstract □□ Paper □□ Filtered Article □□ Summary □□ Review/Meta-Analysis □□ College/Society/Guideline Paper □ Other Research □□ Abbreviated Citation: \_searched Dynamed for BPPV\_\_\_\_\_ Strengths: indexed summary with direct links to supporting evidence Weaknesses:\_takes a minute to log in\_\_\_\_\_ Take-Home Message: no evidence of benefit, potential adverse effects. Medication not recommended for BPPV\_\_\_\_\_ #2 Resource: Abstract □□ Paper □□ Filtered Article □□ Summary □□ Review/Meta-Analysis □□ College/Society/Guideline Paper ☑ Other Research □□ Abbreviated Citation: Am Academy of Neurology Guidelines (thru TRIP) Strengths:\_indexed guidelines and provides level of evidence\_\_\_\_\_ Weaknesses: \_no link to supporting primary research\_\_\_\_\_ Take-Home Message: \_Same as Dynamed essentially.\_\_\_\_\_ #3 Resource: Abstract □□ Paper □□ Filtered Article □□ Summary □□ Review/Meta-Analysis □□ College/Society/Guideline Paper □ Other Research □□ Abbreviated Citation: \_www.fpnotebook.com BPPV article\_\_\_\_\_ Strengths: very brief, easy to access and read quickly Weaknesses: \_minimal references to outdated sources, doesn't appear to be very thorough or rigorous site Take-Home Message: \_Lists potential therapies, but no mention of efficacy or evidence.\_ **Bottom-line:** There doesn't appear to be any conclusive evidence of benefit for antivertigo medication (meclizine, scopolamine, betahistine, etc.) in the treatment of BPPV. There is good evidence for Epley's maneuver done by clinicians and even for patients to do at home. **Practice** (These findings had a): Large Change **□**□ Small Change □□ Reassured □□ No Help □□

□ I do **not** want my BEAR (name removed) on the Dept EBM Website

## BEAR Work-Sheet (Title): \_Cymbalta (SNRI) and chronic pain\_ Name of Resident: **Date**: October 19, 2011 **Question:** Is Cymbala (duloxetine) effective for chronic low back pain? **Search**: (Check all that apply) Pubmed/Ovid/Medline: □□ Filtered Resources: □□ Summary/Review Sites: ⊡□ College/Society/Guidelines: □□ Other: □ ( Describe: \_\_\_\_\_) Number of Resources Reviewed: \_5\_ TRIP, EBM, UpToDate, ACP Pier, Cochran Library **Resources** (Top 3) #1 Resource: Abstract □□ Paper Filtered Article □□ Summary □□UpToDate Review/Meta-Analysis □□ College/Society/Guideline Paper □ Other Research □□ - Abbreviated Citation: Chronic pain management Strengths:\_randomized trial\_ Weaknesses:\_sponsored by the drug manufacturer, the difference that was found was small (<1 point on the Brief Pain Inventory and <2 points on the Roland Morris Disability Questionnaire)\_\_\_\_\_ \_Pts were more likely to discontinue use of duloxetine compared to placebo due to adverse effects \_\_\_\_\_ Take-Home Message:\_Insufficient evidence to suggest this is a viable option in CLBP\_\_ **#2 Resource**: Abstract □□ Paper □□ Filtered Article **□**□ Summary $\Box$ Review/Meta-Analysis □□ College/Society/Guideline Paper □ Other Research □□ Abbreviated Citation: \_a dbl blind, randomized trial of duloxetine vs. placebo in the management of chronic low back pain\_ - 13 wk, dbl blind study looking at 20, 60, and 120 mg of duloxetine vs. placebo. Their primary measure was 60 mg of duloxetine vs. placebo on weekly mean 24 hr average pain. Secondary measures included BPI and RMDQ, PGI-I (pt's global impressions of improvement), safety and tolerability. Entrance eligibility included pts with >6 months of pain in LB or LB with proximal radiation and pain rating >4.\_\_\_\_\_ 404 enrolled, 267 completed Strengths:\_dbl-blind, vs. placebo\_\_\_\_ Weaknesses: \_study design, funding and drugs supplied by the company, Eli Lilly, and authors may be minor shareholders\_\_\_\_\_ Take-Home Message: \_no difference in dosage for 24 hr avg weekly pain scale, more stopped the 120 mg dose d/t s/e. A significant difference was noted from wks 3-11 in relieving pain, but not at 12-13 wks. Duloxetine would not be in the first few lines of treatment options.

□ I do **not** want my BEAR (name removed) on the Dept EBM Website

#3 Resource: Abstract	•		•
Review/Meta-Analysis	_	lopram vs. duloxetine	
blinded		nopram vs. daioxeane	m clbi, kci, not
Escitalo	pram has never been	shown to be useful in ny efficacy in its use i	
- Strengtl duloxet	ns:_did a 13 wk study ine. The primary outc	comparing 20 mg esc come measure was 24	italopram to 60 mg hr avg weekly pain.
Short Forwas four points of short for trial, an contribution was due	orm Health Survey. 8 and to exist b/w these 2 on a pain scale. Both orm health survey. Clid despite, a path analysted to the overall oute to the analgesic effects	O pts participated. Not 2 drugs. Avg pain implicitly depressed pts visis was done to see if come and found the met.	were excluded from the mood improvement ajority of the effect
	esses:_not blinded, no ovement	placebo, despite impr	ovement, small margir
Take-Home Message: based on their efficacy antidepressant use was	_Uncertain whether the or on confounding variation	riables since not blind	led. Other
antiuepressant use was	are a prior to trial, an	id no pracebo compari	son
<b>Bottom-line:</b> The evictange is small and no options for chronic low	t likely to warrant bei		
Practice (These findin Large Change □□	•	Reassured $\Box$	No Help □□